Preparation and characterization of a DOTA-lysine-biotin conjugate as an effector molecule for pretargeted radionuclide therapy
Related Experiment Video
Updated: Oct 13, 2026
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
James Hainsworth1, Peter Harrison, Stephen J Mather
1Cancer Research UK, Nuclear Medicine Group, St. Bartholomew's Hospital, London.
Abstract:
Pretargeted radionuclide therapy depends on the establishment of a high concentration of secondary binding sites at a tumor to which low-molecular weight radiolabeled effector molecules can be directed. This study describes the simple synthesis of an effector molecule and its subsequent characterization to determine the extent to which it complied with the ideal requirements of such a compound. (Epsilon)-DOTA-(alpha)-biotinamidolysine (DLB) was synthesized in high yield and purity using conventional SPPS methodology. High radiochemical purities were obtained when labeled with several potentially useful radionuclides. The radiolabeled analogue bound to streptavidin efficiently with a stoichiometry similar to that of native biotin and showed high stability in serum and upon challenge with acid conditions. Biodistribution studies in normal animals showed a rapid rate of clearance from the blood and low retention of radioactivity by normal tissues. This design of effector molecule therefore shows promise for further pretargeted radionuclide therapy studies.
Insights
A novel effector molecule, (Epsilon)-DOTA-(alpha)-biotinamidolysine (DLB), was synthesized for pretargeted radionuclide therapy. This compound demonstrates efficient targeting and rapid clearance, showing promise for future cancer treatments.
Area of Science:
- Bioconjugate Chemistry
- Radiopharmaceutical Science
- Oncology
Background:
- Pretargeted radionuclide therapy requires specific targeting of tumor-associated secondary binding sites.
- Development of suitable low-molecular-weight effector molecules is crucial for effective delivery of radionuclides.
- Existing effector molecules may have limitations in stability, targeting efficiency, or clearance kinetics.
Purpose of the Study:
- To synthesize and characterize a novel effector molecule, (Epsilon)-DOTA-(alpha)-biotinamidolysine (DLB), for pretargeted radionuclide therapy.
- To evaluate the binding affinity, stability, and biodistribution profile of the synthesized DLB molecule.
- To assess the potential of DLB as a component in future pretargeted radionuclide therapy strategies.
Main Methods:
- Solid-phase peptide synthesis (SPPS) was employed for the high-yield and high-purity synthesis of DLB.
- Radiolabeling of DLB with various radionuclides was performed to assess radiochemical purity.
- In vitro studies evaluated the binding stoichiometry to streptavidin and stability under serum and acidic conditions.
- In vivo biodistribution studies in normal animals were conducted to assess clearance and tissue retention.
Main Results:
- DLB was synthesized with high yield and purity using SPPS.
- Radiolabeled DLB achieved high radiochemical purities with multiple radionuclides.
- The radiolabeled DLB exhibited efficient binding to streptavidin, comparable to native biotin, and demonstrated high stability.
- Biodistribution studies revealed rapid blood clearance and low retention in normal tissues.
Conclusions:
- The synthesized (Epsilon)-DOTA-(alpha)-biotinamidolysine (DLB) effector molecule meets ideal requirements for pretargeted radionuclide therapy.
- DLB demonstrates favorable characteristics including efficient streptavidin binding, high stability, and rapid clearance.
- This novel effector molecule holds significant promise for advancing pretargeted radionuclide therapy applications.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
